Following the numerous press interpretations of the last few hours, AIFA specifies that the position of the Technical Scientific Commission has remained unchanged with respect to that expressed in the meeting on Saturday 30 January. Pending further studies, the indication for the AstraZeneca vaccine remains preferentially for the population aged 18 to 55 years and without severe disease, for which more robust data are available.
More evidence on the benefit / risk ratio of the AstraZeneca vaccine is expected before suggesting its administration in older subjects.